GRI Bio (GRI) vs Processa Pharmaceuticals (PCSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Processa Pharmaceuticals is the larger company by market cap ($3.8 million vs $3.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | GRI | PCSA |
|---|---|---|
| Share price | $1.68 | $1.35 |
| Market cap | $3.67M | $3.77M |
| 1-day change | -9.19% | -4.93% |
| EPS (TTM) | $-14.71 | $-4.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $64.12 | $11.08 |
| 52-week low | $1.36 | $1.35 |
| Distance from 52-week high | -97.38% | -87.81% |
| Average volume | 328.06K | 224.79K |
| Shares outstanding | 2.19M | 2.79M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
GRI vs PCSA FAQ
Which is bigger, GRI Bio or Processa Pharmaceuticals?
Processa Pharmaceuticals (PCSA) is larger, with a market capitalization of $3.77M compared with $3.67M for GRI Bio (GRI).
Are GRI Bio and Processa Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.